Physician
Eye Centers of America, LLC
Eye Centers of America, LLC was paid $26.34M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 92014, Ophthalmological services: medical examination and evaluation, comprehensive, established patient — 18% of everything it billed.
33Billing provider infoEYE CENTERS OF AMERICA, LLC
BLOOMFIELD, NJ 07003
BLOOMFIELD, NJ 07003
33aNPI1649563636assigned 05/24/2011
33bProvider typeOphthalmology Physician
28Total paid$26.34M
24GClaims519,670
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ophthalmology Physician providers in New Jersey
Rank by total paid#1 of 213
Median peer was paid$20K
This provider vs. median1,343×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,502 | $1.39M | |
| 2019 | 44,224 | $1.79M | |
| 2020 | 50,294 | $2.41M | |
| 2021 | 73,912 | $4.27M | |
| 2022 | 87,657 | $4.75M | |
| 2023 | 117,687 | $6.22M | |
| 2024incomplete | 111,394 | $5.52M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 18% | 72,009 | 66,030 | $4.69M |
| J0178 | Injection, aflibercept, 1 mg | 12% | 4,620 | 3,214 | $3.22M |
| J2778 | Injection, ranibizumab, 0.1 mg | 12% | 6,615 | 4,710 | $3.12M |
| J9035 | Injection, bevacizumab, 10 mg | 9.7% | 12,544 | 10,155 | $2.55M |
| 67028 | Intravitreal injection of a pharmacologic agent | 6.1% | 32,656 | 25,384 | $1.62M |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 5.4% | 12,715 | 12,160 | $1.43M |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 5.3% | 29,798 | 26,380 | $1.39M |
| 92134 | 5.0% | 62,244 | 57,209 | $1.32M | |
| 92250 | 3.2% | 34,515 | 31,140 | $854K | |
| 92015 | Determination of refractive state | 3.2% | 46,307 | 42,482 | $843K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.1% | 19,157 | 16,714 | $824K |
| 92235 | 2.3% | 9,770 | 9,125 | $596K |
63 more codes
| 99204 | Doctor's office visit, new patient (more involved) | 2.0% | 5,171 | $537K |
| 99203 | Doctor's office visit, new patient (routine) | 1.9% | 6,833 | $496K |
| 92287 | 1.7% | 5,579 | $449K | |
| 92201 | 1.6% | 29,349 | $431K | |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.4% | 6,184 | $365K |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 1.3% | 668 | $331K |
| 92083 | <1% | 9,477 | $257K | |
| 92226 | <1% | 19,727 | $255K | |
| 92133 | <1% | 10,020 | $171K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 511 | $103K |
| 92202 | <1% | 12,304 | $91K | |
| 92020 | <1% | 7,159 | $83K | |
| 92225 | <1% | 3,519 | $60K | |
| 68761 | <1% | 1,190 | $48K | |
| 92136 | <1% | 1,730 | $35K | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 133 | $34K |
| 92499 | <1% | 616 | $23K | |
| 76519 | <1% | 861 | $20K | |
| 92002 | <1% | 284 | $19K | |
| 76512 | <1% | 913 | $17K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 73 | $15K |
| 76514 | <1% | 1,607 | $12K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 366 | $10K |
| 92060 | <1% | 105 | $7K | |
| 67210 | <1% | 17 | $6K | |
| 65855 | <1% | 103 | $6K | |
| 92273 | <1% | 31 | $2K | |
| 92286 | <1% | 288 | $2K | |
| 66821 | <1% | 26 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 834 | $1K |
| 92132 | <1% | 58 | $1K | |
| 92285 | <1% | 359 | $1K | |
| 92025 | <1% | 34 | $909.23 | |
| 83037 | <1% | 1,027 | $830.64 | |
| 76513 | <1% | 16 | $717.98 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 126 | $148.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12 | $122.79 |
| 99024 | <1% | 3,968 | $20.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 16 | $10.71 |
| G8397 | Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy | <1% | 2,697 | $5.92 |
| 5010F | <1% | 2,687 | $4.13 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | <1% | 10,798 | $1.00 |
| 4177F | 0% | 3,687 | $0.00 | |
| 1036F | 0% | 842 | $0.00 | |
| 3285F | 0% | 755 | $0.00 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 187 | $0.00 |
| 3284F | 0% | 840 | $0.00 | |
| 3072F | 0% | 187 | $0.00 | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 355 | $0.00 |
| G8952 | Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given | 0% | 549 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 96 | $0.00 |
| 2019F | 0% | 228 | $0.00 | |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 13 | $0.00 |
| G8428 | Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given | 0% | 14 | $0.00 |
| G9974 | Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity | 0% | 3,440 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 12,226 | $0.00 |
| 2027F | 0% | 1,007 | $0.00 | |
| 2022F | 0% | 2,863 | $0.00 | |
| 0517F | 0% | 1,406 | $0.00 | |
| 2021F | 0% | 156 | $0.00 | |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 304 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 31 | $0.00 |
| 2026F | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHIGGINS, PATRICK (CEO)
| Provider | Location | Paid |
|---|---|---|
| Mission Hills Health Care,inc, | San Diego, CA | $36K |
| NY Retina Eye Care, PLLC | Suffern, NY | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.